Li Tianhang, Liu Tianyao, Zhu Wenjie, Xie Shangxun, Zhao Zihan, Feng Baofu, Guo Hongqian, Yang Rong
Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Institute of Urology, Nanjing University, Nanjing, 210008, People's Republic of China.
Clin Med Insights Oncol. 2021 Aug 5;15:11795549211035540. doi: 10.1177/11795549211035540. eCollection 2021.
Immune-checkpoint blockade (ICB) demonstrated inspiring effect and great promise in anti-cancer therapy. However, many obstacles, such as drug resistance and difficulty in patient selection, limited the efficacy of ICB therapy and awaited to be overcome. By timely identification and intervention of the key immune-suppressive promotors in the tumor microenvironment (TME), we may better understand the mechanisms of cancer immune-escape and use novel strategies to enhance the therapeutic effect of ICB. Myeloid-derived suppressor cell (MDSC) is recognized as a major immune suppressor in the TME. In this review, we summarized the roles MDSC played in the cancer context, focusing on its negative biologic functions in ICB therapy, discussed the strategies targeted on MDSC to optimize the diagnosis and therapy process of ICB and improve the efficacy of ICB therapy against malignancies.
免疫检查点阻断（ICB）在抗癌治疗中显示出令人鼓舞的效果和巨大前景。然而，许多障碍，如耐药性和患者选择困难，限制了ICB治疗的疗效，有待克服。通过及时识别和干预肿瘤微环境（TME）中的关键免疫抑制促进因子，我们可以更好地理解癌症免疫逃逸的机制，并采用新策略提高ICB的治疗效果。髓源性抑制细胞（MDSC）被认为是TME中的主要免疫抑制因子。在本综述中，我们总结了MDSC在癌症背景下所起的作用，重点关注其在ICB治疗中的负面生物学功能，讨论了针对MDSC的策略，以优化ICB的诊断和治疗过程，并提高ICB治疗恶性肿瘤的疗效。
